Literature DB >> 24150826

[Spironolactone in dermatological treatment. On and off label indications].

C M Salavastru1, K Fritz, G S Tiplica.   

Abstract

There are no currently FDA/EMEA-approved dermatologic indications for spironolactone and its off-label uses are, among others, female acne, female pattern hair loss, hidradenitis suppurativa or hirsutism. The rationale behind these relays on the mechanism of action of spironolactone which interferes with the hormone-controlled sebum and sweat gland secretion and with androgen stimulated hair growth. The average dose used by the dermatologits is 50-100 mg daily. It should not be used in pregnant and lactating women and it is not used in men due to the risk of feminization. Although further studies to assess its efficacy and safety are necessary, currently spironolactone is regarded as a useful tool in the dermatologic treatment armamentarium.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24150826     DOI: 10.1007/s00105-013-2597-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  26 in total

1.  Evaluation and treatment of male and female pattern hair loss.

Authors:  Elise A Olsen; Andrew G Messenger; Jerry Shapiro; Wilma F Bergfeld; Maria K Hordinsky; Janet L Roberts; Dow Stough; Ken Washenik; David A Whiting
Journal:  J Am Acad Dermatol       Date:  2005-02       Impact factor: 11.527

Review 2.  Pharmacologic interventions for hidradenitis suppurativa: what does the evidence say?

Authors:  Raed Alhusayen; Neil H Shear
Journal:  Am J Clin Dermatol       Date:  2012-10-01       Impact factor: 7.403

3.  Use of spironolactone in treatment of hirsutism.

Authors:  D C Cumming
Journal:  Cleve Clin J Med       Date:  1990-05       Impact factor: 2.321

4.  Nonestrogenic drugs and breast cancer.

Authors:  D A Danielson; H Jick; J R Hunter; A Stergachis; S Madsen
Journal:  Am J Epidemiol       Date:  1982-08       Impact factor: 4.897

Review 5.  Cutaneous androgen metabolism: basic research and clinical perspectives.

Authors:  WenChieh Chen; Diane Thiboutot; Christos C Zouboulis
Journal:  J Invest Dermatol       Date:  2002-11       Impact factor: 8.551

6.  Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands.

Authors:  H Akamatsu; C C Zouboulis; C E Orfanos
Journal:  J Invest Dermatol       Date:  1992-10       Impact factor: 8.551

7.  Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl.

Authors:  Anosha Yazdabadi; Jack Green; Rod Sinclair
Journal:  Australas J Dermatol       Date:  2009-05       Impact factor: 2.875

8.  The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.

Authors:  J Imperato-McGinley; T Gautier; L Q Cai; B Yee; J Epstein; P Pochi
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

9.  Metabolism of dihydrotestosterone to 5 alpha-androstane-3 alpha, 17 beta-diol glucuronide is greater in the peripheral compartment than in the splanchnic compartment.

Authors:  D M Duffy; R S Legro; L Chang; F Z Stanczyk; R A Lobo
Journal:  Fertil Steril       Date:  1995-10       Impact factor: 7.329

Review 10.  Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.

Authors:  C Farquhar; O Lee; R Toomath; R Jepson
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  2 in total

Review 1.  Beneficial Extracardiac Effects of Cardiovascular Medications.

Authors:  Asra K Butt; Jay Patel; Hamid Shirwany; Qasim Mirza; Jonathan Hoover; Rami N Khouzam
Journal:  Curr Cardiol Rev       Date:  2022

2.  Serendipity and its role in dermatology.

Authors:  Arijit Coondoo; Sujata Sengupta
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.